FDA Approves Bysanti (Milsaperidone): First New Antipsychotic Mechanism in 30 Years

What Is Bysanti and How Does It Work?

Bysanti (milsaperidone) works through a mechanism fundamentally different from antipsychotics developed since chlorpromazine was first used in psychiatry in 1952. All previously approved antipsychotics — from first-generation drugs like haloperidol to second-generation agents like olanzapine, risperidone, and quetiapine — achieve their therapeutic effect primarily by blocking dopamine D2 receptors in the mesolimbic pathway. While effective at reducing positive psychotic symptoms (hallucinations, delusions), D2 blockade also causes a range of debilitating side effects: extrapyramidal symptoms (EPS), tardive dyskinesia, elevated prolactin, and the metabolic syndrome (weight gain, diabetes, dyslipidemia) that collectively contribute to significantly reduced life expectancy in schizophrenia patients.

Bysanti instead activates trace amine-associated receptor 1 (TAAR1), an intracellular receptor expressed in dopaminergic and serotonergic neurons that modulates neurotransmitter release through negative feedback mechanisms. Early clinical research on TAAR1 agonism, including a Phase 2 trial published in the New England Journal of Medicine in 2020, demonstrated that this mechanism could reduce excessive dopaminergic signaling in the mesolimbic pathway (addressing positive symptoms) while potentially enhancing dopaminergic and glutamatergic transmission in the prefrontal cortex (which may improve negative symptoms and cognitive function). Because TAAR1 agonists do not directly block D2 receptors, they are expected to have a lower risk of movement disorders and metabolic effects compared to current treatments.

Bysanti is administered orally once daily. It also has activity at serotonin receptors, which may contribute to additional mood-stabilizing properties. As with many psychiatric medications, dose adjustments may be recommended for patients with certain metabolic enzyme variations or those taking medications that affect drug metabolism.

How Effective Is Bysanti Compared to Current Treatments?

The FDA approval was based on pivotal Phase 3 clinical trials in adults with schizophrenia and bipolar I disorder. In the schizophrenia trials, Bysanti demonstrated statistically significant and clinically meaningful reductions in PANSS (Positive and Negative Syndrome Scale) total scores compared to placebo. The magnitude of improvement was considered comparable to that seen with established antipsychotic medications in similar trial designs.

In a separate trial for acute manic or mixed episodes of bipolar I disorder, Bysanti significantly reduced YMRS (Young Mania Rating Scale) scores compared to placebo, demonstrating antimanic efficacy in line with existing treatment options.

The key differentiator for Bysanti was its side effect profile. In the clinical trial program, weight gain with Bysanti was minimal and comparable to placebo, in contrast to established antipsychotics such as olanzapine, which is associated with average weight gain of 4–7 kg over similar treatment periods, and risperidone, which commonly causes weight gain of 2–3 kg. Rates of extrapyramidal symptoms and prolactin elevation with Bysanti were low and similar to placebo, whereas these side effects occur frequently with conventional D2-blocking antipsychotics. The most commonly reported side effects of Bysanti included somnolence, headache, and nausea.

What Does This Mean for Patients with Schizophrenia?

The approval of Bysanti addresses one of the most significant unmet needs in psychiatry: the devastating metabolic side effects of current antipsychotics. The landmark CATIE trial, published in the New England Journal of Medicine in 2005, found that 74% of patients with schizophrenia discontinued their antipsychotic medication within 18 months, with side effects and lack of efficacy being major contributing factors. Weight gain — sometimes exceeding 10 kg or more in the first year of treatment with certain antipsychotics — contributes to a dramatically elevated risk of type 2 diabetes, cardiovascular disease, and premature death. Research consistently shows that people with schizophrenia die an average of 15–20 years earlier than the general population, with cardiometabolic disease being the leading cause of this excess mortality.

Experts in psychiatry have described a TAAR1 agonist antipsychotic without significant metabolic liability as a potentially transformative advance — the most important conceptual shift in antipsychotic pharmacology since the introduction of clozapine in 1989. In the United States, approximately 3.5 million people live with schizophrenia and millions more are affected by bipolar disorder, creating a large population that could potentially benefit from a treatment with an improved side effect profile.

As with other newly approved branded antipsychotic medications, Bysanti's cost is expected to be significant, and the manufacturer has indicated plans for a patient assistance program. An extended-release injectable formulation is reportedly under development, which could further improve adherence for patients who struggle with daily oral medication.